Comparing the current results to its competitors, Lisata Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, slower than the combined decrease of the LSTA's competitors by -41.78 %, recorded in the same quarter.
March 5, 2025
In a bold move to redefine the pharmaceutical industry s drug development approach, Lisata Therapeutics Inc. and GATC Health have consummated the initial phase of a strategic collaboration aimed at mitigating risks and expediting the drug development continuum. The alliance harnesses GATC s cutting-edge AI-driven, validated Multiomics Advanced Technology platform, designed to optimize and economize the traditionally lengthy and costly drug discovery process.This partnership is a testament to the transformative power of artificial intelligence in biotechnology. GATC Health s proprietary platform enables a rapid optimization process that can foresee the potential pitfalls in drug development, thereby reducing ...
July 10, 2024
:Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive and lethal liver cancer with limited treatment options. Recent advancements have shed light on Certepetide, a novel therapeutic agent, showing promising effects in preclinical models by promoting immune cell infiltration into tumors and inhibiting metastasis. This article aims to summarize the findings of several studies conducted on the efficacy and mechanism of action of Certepetide, with a focus on its potential to revolutionize the treatment landscape for ICC.Intrahepatic cholangiocarcinoma (ICC), a subtype of cholangiocarcinoma originating from the bile ducts within the liver, is characterized by its aggressive nature and poor prognosis. Stan...
April 9, 2024
BASKING RIDGE, N.J., April 09, 2024 - Lisata Therapeutics, Inc. (Nasdaq: LSTA), a prominent clinical-stage pharmaceutical company dedicated to pioneering innovative therapies for advanced solid tumors and other severe ailments, has garnered significant attention with its latest announcement. Lisata revealed today that its lead product candidate, LSTA1, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma, an exceptionally rare cancer found predominantly in children, adolescents, and young adults. This milestone achievement follows the recent accolade of Rare Pediatric Disease Designation for osteosarcoma, as revealed by the Company on...
January 4, 2024
The geme of Oncology has been revolutionized with a plethora of cutting-edge therapeutics, yet the grim burden of gastroesophageal adenocarcinoma stands resilient. Oncology demands continuous innovation, and Lisata Therapeutics has answered the call, demonstrating the potential of their lead investigational product, LSTA1, in metastatic gastroesophageal adenocarcinoma. This landmark publication emphasizes the significant strides made in confronting this deadly disease with an implementation entirely distinctive from conventional treatments. LSTA1, Lisata Therapeutic s lead investigational product has demonstrated a complete response in a metastatic gastroesophageal adenocarcinoma patient when administered co...
Aprea Therapeutics Inc is a biopharmaceutical company with a business model focused on developing and commercializing innovative cancer therapies. They aim to leverage their proprietary discovery platform to identify and develop small molecules that selectively target and restore the tumor suppressor protein p53. Their business strategy includes conducting clinical trials, seeking regulatory approvals, and partnering with other organizations for commercialization and distribution.
Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.
Avid Bioservices Inc is a biopharmaceutical company that provides contract development and manufacturing services for the production of biologics, including antibodies and mammalian cell-based therapies, to pharmaceutical and biotechnology companies.
Essa Pharma Inc.'s business model revolves around the development of targeted small molecule therapeutics for the treatment of cancer. The company aims to address the unmet medical needs of patients with advanced and metastatic forms of prostate and breast cancer. By leveraging their expertise in clinical development and precision medicine, Essa Pharma aspires to bring innovative and effective treatments to market, ultimately improving patient outcomes.
Sources:
Lisata Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lisata Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
